In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor

Journal of Cellular Physiology

Volumn 205, Issue 3, 2005, Pages 335-343

  Hu, Pinliang ^a   Feng, Jiannan ^a   Zhou, Tao ^b   Wang, Jianing ^a   Jing, Baofeng ^b   Yu, Ming ^a   Hu, Meiru ^a   Zhang, Xuemin ^b   Shen, Beifen ^a   Guo, Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GREEN FLUORESCENT PROTEIN; HERSTATIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; COMPUTER AIDED DESIGN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GROWTH INHIBITION; IMMUNOPRECIPITATION; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; EXTRACELLULAR SPACE; FLUORESCENCE RESONANCE ENERGY TRANSFER; IMMUNOPRECIPITATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TRANSFECTION;

ANIMALIA;

EID: 27744472328     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20409     Document Type: Article

References (55)

1. Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton, GM. 2001. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20:5199-5209.
2. Baker D, Sali A. 2001. Protein structure prediction and structural genomics. Science 294:93-96.
3. Bargmann CI, Hung MC, Weinberg RA. 1986. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230.
4. Beerli RR, Weis W, Hynes NE. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269:23931-23936.
5. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signaling. Nature 411:355-365.
6. Burden S, Yarden Y. 1997. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis. Neuron 18:847-855.
7. Carraway KL, Cantley LC. 1994. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5-8.
8. Cho HS, Mason K, Ramyar K, Staley AM, Gabelli SB, Denney DW, Jr., Leahy DJ. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760.
9. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648.
10. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139.
11. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. 1996. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 96:10869-10874.
12. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. 1994. The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109-2123.
13. Earp HS, Dawson TL, Li X, Yu H. 1995. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115-132.
14. Fanelli F, Menziani C, Scheer A, Cotecchia S, De Benedetti PG. 1998. Ab initio modeling and molecular dynamics simulation of the a1b-Adrenergic receptor activation. Methods 14:302-317.
15. Fletcher R, Powell MJD. 1963. A rapidly convergent descent method for minimization. Comput J 6:163-168.
16. Galaktionov S, Nikiforovich GV, Marshall GR. 2001. Ab initio modeling of small, medium and large loops in proteins. Biopolymers 60:153-168.
17. Gallagher K, Sharp K. 1998. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys J 75:769-776.
18. Garnier J, Gibrat JF, Robson B. 1996. GOR secondary structure prediction method version IV. In Doolittle RF, editor. Methods in Enzymology. Academic Press UK, 266. pp 540-553.
19. Garrett TP, Mckern NM, Lou M. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763-773.
20. Goodsell DS, Olson AJ. 1990. Automated docking of substrates to proteins by simulated annealing. Proteins 8:195-202.
21. Graus-Porta D, Beerli RR, Hynes NE. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182-1191.
22. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655.
23. Hung MC, Schechter AL, Chevray PY, Stern DF, Weinberg RA. 1986. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 83:261-264.
24. Hynes NE, Stern DF. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184.
25. Jones DT. 1997. Successful ab initio prediction of the tertiary structure of NK-lysin using multiple sequences and recognized supersecondary structural motifs. Proteins 1(suppl):185-191.
26. Justman Q, Clinton GM. 2002. Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest. J Biol Chem 277:20618-20624.
27. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 15:254-264.
28. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sala M, Yarden Y. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96:4995-5000.
29. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. 2000. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79.
30. Ma YJ, Hill DF, Creswick KE, Costa ME, Cornea A, Lioubin MN, Plowman GD, Ojeda SR. 1999. Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development. J Neurosci 19:9913-9927.
31. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Demard F, Schneider M, Milano G. 2001. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 37:2169-2177.
32. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. 2002. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107:247-258.
33. Moulder SL, Yokes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. 2001, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895.
34. Ogiso H, Ishitani R, Nureki O. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787.
35. Olayioye MA, Nevem RM, Lane HA. 2000. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167.
36. Ortiz AH, Kolinski A, Rotkiewicz P, Ilkowsk B, Skolnick J. 1999. Ab initio folding of proteins using restraints derived from evolutionary information. Proteins 3(suppl):177-185.
37. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R. 2000. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 18:194-198.
38. Pillardy J, Czaplewski C, Liwo A, Lee J, Ripoll DR, Kazmierkiewicz R, Oldziej S, Wedemeyer WJ, Gibson KD, Arnautova YA, Saunders J, Ye YJ, Scheraga HA, 2001. Recent improvements in prediction of protein structure by global optimization of a potential energy function. Proc Natl Acad Sci USA 98:2329-2333.
39. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467.
40. Ramachandran GN, Ramakrishnan C, Sasisekharan V. 1963. Conformation of polypeptides and proteins. J Mol Biol 7:95-99.
41. Riese DJ II, van Raaij TM, Plowman GD, Andrews GC, Stern DF. 1995. Cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15:5770-5776.
42. Samudrala R, Xia Y, Huang E, Levitt M. 1999. Ab initio protein structure prediction using a combined hierarchical approach. Proteins 3(suppl):194-198.
43. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
44. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
45. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344:783-792.
46. Tzahar E, Yarden Y. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377:M25-M37.
47. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287.
48. Ullrich A, Shepard HM. 1991. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1:72-82.
49. Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. 2000. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol Lett 75:61-67.
50. van Gunsteren WF, Berendsen HJ. 1984. Computer simulation as a tool for tracing the conformational differences between proteins in solution and in the crystalline state. J Mol Biol 176:559-564.
51. Wada T, Qian X, Greene MI. 1990. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339-1347.
52. Wang JN, Feng JN, Yu M, Xu M, Shi M, Zhou T, Yu XD, Shen BF, Guo N. 2004. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies. Mol Immunol 40:963-969.
53. Xia Z, Liu Y. 2001. Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscope. Biophys J 81:2395-2402.
54. Yarden Y. 2001. Biology of HER2 and its importance in breast cancer. Oncology 61:1-13.
55. Yip YL, Ward RL. 2002. Anti-ErbB2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 50:569-587.